Sarcopenia is the loss of muscle strength, mass, and function, which is often exacerbated by
chronic comorbidities including cardiovascular diseases, chronic kidney disease, and …

Metformin is a first-line therapy for the treatment of type 2 diabetes, due to its robust glucose-
lowering effects, well-established safety profile, and relatively low cost. While metformin has …

Background: Measures to quantify changes in the pace of biological aging in response to
intervention are needed to evaluate geroprotective interventions for humans. Previously, we …

The geroscience hypothesis proposes that therapy to slow or reverse molecular changes
that occur with aging can delay or prevent multiple chronic diseases and extend healthy …

The search for biomarkers that quantify biological aging (particularly 'omic'-based
biomarkers) has intensified in recent years. Such biomarkers could predict aging-related …

Background Physical frailty and sarcopenia show extensive clinical similarities. Whether
biomarkers exist that are shared by the two conditions is presently unclear. Methods We …

For several decades, understanding ageing and the processes that limit lifespan have
challenged biologists. Thirty years ago, the biology of ageing gained unprecedented …

Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the
mechanisms underlying the plasma glucose level-lowering effects of metformin (1, 1 …

Biological aging is the gradual, progressive decline in system integrity that occurs with
advancing chronological age, causing morbidity and disability. Measurements of the pace of …

Introduction The number of individuals worldwide with Alzheimer's disease (AD) is growing
at a rapid rate. New treatments are urgently needed. We review the current pipeline of drugs …